Comparative Pharmacology
Head-to-head clinical analysis: FELBATOL versus TRIDIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELBATOL versus TRIDIONE.
FELBATOL vs TRIDIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Increases seizure threshold by modulating voltage-gated sodium channels and enhancing GABA-ergic inhibition.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
300-600 mg orally three times daily; titrate to seizure control.
None Documented
None Documented
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
16-24 hours (trimethadione); dimethadione (active metabolite) has a half-life of ~6-12 days, leading to drug accumulation.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Renal: ~70% as unchanged drug and metabolites (including dimethadione); biliary/fecal: minimal (<10%).
Category C
Category C
Anticonvulsant
Anticonvulsant